Editorial: Come as You R(NA): Post-transcriptional Regulation Will Do the Rest

Oriane Mauger^1*Michael A Kiebler^2*Clémence Bernard^3*

• ¹Max Planck Institute of Psychiatry, Munich, Germany
• ²Biomedical Center, Department of Cell Biology and Anatomy, Medical Faculty, Ludwig-Maximilians-University, Planegg-Martinsried, Germany
• ³Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, United Kingdom

widespread programs, the logic of their regulation and their physiological relevance have recently taken their full meaning. Indeed, PTPs tightly parallel the intricacy of the brain's spectacular diversity of cells with complex morphologies that need to integrate many extrinsic and intrinsic signals (Bauer et al., 2022;Bauer, de Queiroz, Kiebler, & Besse, 2023;Darnell, 2013;Furlanis & Scheiffele, 2018;Holt, Martin, & Schuman, 2019). This editorial introduces the articles collected in this Research Topic to highlight the recent progress in the field of post-transcriptional control of gene expression in the central nervous system in health and disease (Figure 1).While the diversity of PTPs has been known for several decades, new mechanisms are continuously revealed to have pivotal roles in shaping gene expression for brain development and function. For instance, epitranscriptomics represents a rapidly expanding area of research, with chemical modifications of mRNAs now emerging as being crucial for neurodevelopment and cognitive functions (Tegowski & Meyer, 2024). Dogmas in the PTP field are being revisited: for a long time, only one open-reading frame (ORF) per mRNA was thought to be active, ultimately giving rise to one protein isoform. Recent evidence has however revealed that multiple ORFs within the same mRNA can produce different protein isoforms. Many of these newly identified ORFs are often located in the improperly called 'untranslated regions' of mRNA and code for microproteins that are likely relevant for neuronal cell functions (Duffy, Assad, Kalish, & Greenberg, 2024). Beyond intracellular mechanisms, the intercellular transfer of secreted factors that influence PTPs (de la Cruz-Gambra & Baleriola, 2025) and of transcripts themselves (Taylor & Nikolaou, 2024) have started to be uncovered. For instance, factors secreted by astrocytes were found to regulate local translation of mRNAs located in neighboring neurons in culture (de la Cruz-Gambra & Baleriola, 2025). While PTPs are mainly investigated for coding RNAs, non-coding (nc) RNAs are also under post-transcriptional control. Many ncRNAs have been observed in neuronal processes including at synapses (Taylor & Nikolaou, 2024) with an increasing number shown to have coding capacity, revising our textbook vision of gene expression (Duffy et al., 2024;Taylor & Nikolaou, 2024).The interplay between PTPs and other gene expression mechanisms is becoming increasingly evident and appears to control the availability, levels and isoforms of PTP factors. For instance, alternative splicing can control the production of transcription factor isoforms with distinct impact on neurodevelopmental transcription programs (Nazim, 2024). The expression levels of posttranscriptional factors can also be controlled by post-translational modifications. Ubiquitination -a key step of proteostasis -can target RNA-binding proteins (RBPs) such as splicing factors, and subsequently affect the splicing regime in the brain (Elu, Subash, & Louros, 2024). This interplay is also clearly evidenced by the various functions exerted by PTP factors at different stages of the RNA life cycle. Many RBPs, such as RNA helicases and heterogeneous nuclear ribonucleoproteins (hnRNPs), exert distinct roles in different subcellular compartments (Lederbauer, Das, Piton, Lessel, & Kreienkamp, 2024;Tilliole, Fix, & Godin, 2024). The splicing factor polypyrimidine tract binding protein PTBP2 has also been shown to be transported in neuronal processes where it controls local translation (Salehi, Zare, Gandhi, Sendtner, & Briese, 2024). Finally, the interplay between PTPs and other gene expression processes can result from a local synergy, where RNA processing factors can be recruited at regulatory transcription regions such as promoters and enhancers. This crosstalk seems to play a pivotal role in dictating the developing neuronal transcriptome (Ozbulut & Hilgers, 2024).Recent research has revealed a high specificity of PTPs, from subcellular localization to cell type and species differences. In neurons, specific PTPs are observed at the subcellular level, with neuronal processes and synapses exhibiting diverse molecular landscapes (Taylor & Nikolaou, 2024). More broadly, the many neuronal subtypes observed in the brain exhibit distinct transcripts and protein repertoires, to which different PTPs contribute. During development, cellular differentiation and specification are associated with dedicated PTPs (Ozbulut & Hilgers, 2024).Finally, another level of specificity is observed between species, raising the tantalizing hypothesis that PTPs also contribute to species divergence and precise features of individual species across evolution (Dando et al., 2024).Several PTPs have been shown to be dysregulated in a range of neurological diseases. Pathological variants of RBPs such as RNA helicases and hnRNPs have been associated with neurodevelopmental disorders, including developmental delay, intellectual disability and brain anomalies (Lederbauer et al., 2024;Tilliole et al., 2024). Defects in RBPs have been linked to degenerative disorders, ranging from spinal muscular atrophy (Salehi et al., 2024) to the frontotemporal lobar degeneration -amyotrophic lateral sclerosis spectrum and Alzheimer's disease (Tilliole et al., 2024). Defective regulation of protein homeostasis has also been reported in several neurological disorders (Elu et al., 2024).A better understanding of PTPs in both health and disease opens the door to novel therapeutic means (Elu et al., 2024;Salehi et al., 2024). RNA-based tools such as splice-switching oligonucleotides have shown great promise to treat spinal muscular atrophy and amyotrophic lateral sclerosis (Zhang, 2024). RNA-targeting CRISPR-Cas9 technologies (Tegowski & Meyer, 2024) are also being developed, which will offer innovative options for therapeutical interventions.The recent progress described in the articles of this Research Topic is continuously accelerated by major technological advances, such as third generation sequencing and spatial transcriptomics (Taylor & Nikolaou, 2024). This is particularly exemplified by our recent ability to identify RNA modifications, and direct sequencing will provide more opportunities to study their effect at the singlemolecule level (Tegowski & Meyer, 2024). More technical developments, such as single-synapse characterization and live imaging of translation, will bring unprecedented resolution to our understanding of the roles of PTPs in spatio-temporal control of gene expression. Artificial intelligence and machine learning will certainly revolutionize prediction of cis-and trans-regulatory elements. This will facilitate the implementation of emerging antisense oligonucleotide strategies to manipulate PTPs and investigate their functional relevance for neuronal circuits and cognition in vivo.We hope that this Research Topic provides valuable material on the latest advances in PTP research and stimulates new avenues for our long-term goal to elucidate the foundational connections between these processes and brain function. The coming years will undoubtedly lead to a more precise understanding of the various levels of PTP regulation and their consequences, with impact on both basic science and translational investigations.